Table of Contents Purpose of This PDQ Summary General Information Cellular Classification Stage Information
Anterior Urethral Cancer Posterior Urethral Cancer Urethral Cancer Associated With Invasive Bladder Cancer Recurrent Urethral Cancer Get More Information From NCI Changes to This Summary (01/09/2008) More Information
Purpose of This PDQ Summary
This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of urethral cancer. This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board.
Information about the following is included in this summary:
- Prognosis.
- Cellular classification.
- Staging.
- Treatment options by different types of tumors.
This summary is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.
Some of the reference citations in the summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations. Based on the strength of the available evidence, treatment options are described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for reimbursement determinations.
This summary is available in a patient version, written in less technical language, and in Spanish.
Back to Top General Information
The prognosis of urethral cancer depends on its anatomical location and the
depth of invasion. Superficial tumors located in the anterior urethra of both
the female and male are generally curable; deeply invasive lesions or those
lesions located in the posterior urethra, because they are almost always deeply
invasive, are rarely curable by any combinations of therapy.
Female urethral cancer is more common than male urethral cancer, but both
tumors are quite rare. The majority of information comes from cases
accumulated over many decades at major cancer centers. Rarely, melanomas or
periurethral sarcomas can occur.
Back to Top Cellular Classification
The female urethra is lined by transitional cell mucosa proximally and
stratified squamous cells distally. Therefore, transitional cell carcinoma is most common in the proximal urethra and squamous cell carcinoma predominates
in the distal urethra. Adenocarcinoma is found in both locations and arises
from metaplasia of the numerous periurethral glands.
The male urethra is lined by transitional cells in its prostatic and membranous
portion and stratified columnar epithelium to stratified squamous epithelium in
the bulbous and penile portions. The submucosa of the urethra contains
numerous glands. Therefore, urethral cancer in the male can manifest the
histological characteristics of transitional cell carcinoma, squamous cell
carcinoma, or adenocarcinoma.
Except for the prostatic urethra, where transitional cell carcinoma is most
common, squamous cell carcinoma is the predominant histology of urethral
neoplasms. Since transitional cell carcinoma of the prostatic urethra is
usually associated with transitional cell carcinoma of the bladder and/or
transitional cell carcinoma arising in prostatic ducts, it is treated according
to the guidelines for treatment of these primaries and should be separated from
the more distal carcinomas of the urethra.
Back to Top Stage Information
Prognosis is determined both by the anatomical location of the neoplasm, the
size, and the depth of invasion of the primary tumor. The histology of the
primary tumor is of less importance in determining response to therapy and
survival.[1]
Anterior Urethral Cancer
These lesions are often superficial.
- Female: Meatal and/or distal urethral cancer (i.e., the lesions of the distal third of the urethra).
- Male: Penile or anterior portion of the urethra, including the meatus and
pendulous urethra.
Posterior Urethral Cancer
These lesions are often deeply invasive.
- Female: Entire urethral cancer; lesions not clearly limited to the distal
third of the urethra.
- Male: Bulbomembranous and prostatic urethral cancer.
Urethral Cancer Associated with Invasive Bladder Cancer
Approximately 10% of patients with cystectomy for bladder cancer can be
expected to have or develop urethral cancer distal to the urogenital diaphragm.
The 5-year survival associated with urethral cancer is most often determined by
the stage.
Stage Definitions by Depth of Invasion
- Stage 0 (Tis, Ta): Limited to mucosa.
- Stage A (T1): Submucosal invasion.
- Stage B (T2): Infiltrating periurethral muscle or corpus spongiosum.
- Stage C (T3): Infiltration beyond periurethral tissue.
- Female: Vagina, labia, muscle
- Male: Corpus cavernosum, muscle
- Stage D1 (N+): Regional nodes; pelvic and inguinal.
- Stage D2 (N+, M+): Distant nodes; visceral metastases.
References
-
Grigsby PW, Corn BW: Localized urethral tumors in women: indications for conservative versus exenterative therapies. J Urol 147 (6): 1516-20, 1992.
[PUBMED Abstract]
Back to Top Anterior Urethral Cancer
Female Anterior Urethral Cancer
If the malignancy is at or just within the meatus and superficial parameters (stage 0/Tis,
Ta), open excision or electroresection and fulguration is possible. Tumor
destruction using Nd:YAG or CO2 laser vaporization-coagulation represents an
alternative option. For large lesions and more invasive lesions (stage A and stage B,
T1 and T2, respectively), interstitial radiation therapy or a combination of interstitial radiation therapy and
external-beam radiation therapy is an alternative to surgical resection of the distal third of
the urethra. Patients with T3 anterior urethral lesions or lesions treated by
local excision or radiation therapy, which then recur, require anterior
exenteration and urinary diversion.
If inguinal nodes are palpable, frozen section confirmation of tumor is
obtained. If positive for malignancy, ipsilateral node dissection is indicated,
as cure is still achievable with limited regional nodal metastases. If no
inguinal adenopathy exists, node dissection is not recommended, but careful
inguinal palpation is mandatory at 3- to 4-month intervals.[1-3]
Standard treatment options:
- Open excision or electroresection and fulguration, or laser vaporization-coagulation (Tis, Ta, T1 lesions).
- External-beam radiation therapy or interstitial radiation therapy or a combination of both (T1, T2 lesions).
- Anterior exenteration with or without preoperative radiation and diversion
(T3 lesions/recurrent lesions).
Male Anterior Urethral Cancer
If the malignancy is in the pendulous urethra and is superficial, the potential
for cure is high. In the rare case that involves mucosa only (stage 0/Tis, Ta),
resection and fulguration is justified as initial therapy. For infiltrating
lesions in the fossa navicularis, amputation of the glans penis may be adequate
treatment. For lesions involving more proximal portions of the distal urethra,
excision of the involved segment of the urethra, preserving the penile corpora,
may be feasible for superficial tumors. Infiltrating lesions require penile
amputation 2 cm proximal to tumor. Local recurrences after amputation
are rare. The role for radiation therapy in the treatment of anterior urethral
carcinoma in the male is not well defined. Some anterior urethral cancers have
been cured with radiation alone.[4,5]
If inguinal nodes are palpable, ipsilateral node dissection is indicated after
frozen section confirmation of tumor, as cure is still achievable with limited
regional nodal metastases. If no inguinal adenopathy exists, node dissection
is not recommended, but careful inguinal palpation is mandatory at 3- to 4-month
intervals.[6-8]
Standard treatment options:
- Open excision or electroresection and fulguration, or laser vaporization-coagulation.
- Amputation of penis (T1, T2, T3 lesions).
- Radiation (T1, T2, T3 lesions, if amputation is refused).
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with anterior urethral cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Johnson DE, O'Connell JR, Delclos L: Carcinoma of the urethra. In: Javadpour N, ed.: Principles and Management of Urologic Cancer. 2nd ed. Baltimore, Md: Williams and Wilkins, 1983, pp 598-621.
-
Bracken RB, Johnson DE, Miller LS, et al.: Primary carcinoma of the female urethra. J Urol 116 (2): 188-92, 1976.
[PUBMED Abstract]
-
Sailer SL, Shipley WU, Wang CC: Carcinoma of the female urethra: a review of results with radiation therapy. J Urol 140 (1): 1-5, 1988.
[PUBMED Abstract]
-
Chao KS, Perez CA: Penis and male urethra. In: Perez CA, Brady LW, eds.: Principles and Practice of Radiation Oncology. 3rd ed. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 1717-1732.
-
Donat S, Cozzi P, Herr H: Surgery of penile and urethral carcinoma. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: Campbell's Urology. 8th ed. Philadelphia: Saunders, 2002, pp 2983-2991.
-
Mullin EM, Anderson EE, Paulson DF: Carcinoma of the male urethra. J Urol 112 (5): 610-3, 1974.
[PUBMED Abstract]
-
Ray B, Canto AR, Whitmore WF Jr: Experience with primary carcinoma of the male urethra. J Urol 117 (5): 591-4, 1977.
[PUBMED Abstract]
-
Webster GD: The urethra. In: Paulson DF, ed.: Genitourinary Surgery. Vol. 2. New York: Churchill Livingston, 1984, pp 399-583.
Back to Top Posterior Urethral Cancer
Female Posterior Urethral Cancer
Lesions of the posterior or entire urethra are usually associated with invasion
and a high incidence of pelvic nodal metastases. The prospects for cure are
limited except in the case of small tumors. The best results have been
achieved with exenterative surgery and urinary diversion with 5-year survivals
ranging from 10% to 20%. It is reasonable to recommend adjunctive radiation
therapy, which is administered preoperatively, in an effort to shrink tumor margins. Pelvic
lymphadenectomy is performed concomitantly since an occasional patient with
nodal metastases will be cured. Ipsilateral inguinal node dissection is
indicated only if biopsy of ipsilateral palpable adenopathy is positive on
frozen section. For tumors that do not exceed 2 cm in greatest
dimension, radiation alone, nonexenterative surgery alone, or the combination
may be sufficient to provide an excellent outcome.[1]
As with male urethral carcinoma, it is reasonable to consider removal of
part of the pubic symphysis and the inferior pubic rami to maximize the
surgical margin and hopefully to reduce local recurrence. The perineal closure
and vaginal reconstruction can be accomplished with the use of myocutaneous
flaps.
The prognosis of female urethral cancer has been related to the size of the
lesion at presentation. For lesions less than 2 cm in diameter, a 60%
5-year survival can be anticipated; for those greater than 4 cm in
diameter, the 5-year survival falls to 13%.[2-5]
Standard treatment options:
- Preoperative radiation followed by anterior exenteration and urinary
diversion with bilateral pelvic node dissection with or without inguinal node
dissection.
- For tumors that do not exceed 2 cm in greatest dimension,
radiation alone, nonexenterative surgery alone, or the combination may be
sufficient to provide an excellent outcome.[1]
Male Posterior Urethral Cancer
Lesions of the bulbomembranous urethra require radical cystoprostatectomy and
en bloc penectomy to achieve adequate margins of resection, minimize local
recurrence, and achieve cure. Pelvic lymphadenectomy is also recommended in
view of the significant incidence of positive nodes, the limited added
morbidity from such dissection, and the potential, though limited,
possibility for cure. Despite extensive surgery, local recurrence does occur
frequently and this event is invariably associated with eventual death from
disease. Five-year survival can be expected in only 15% to 20% of patients.
In an effort to shrink tumor margins, the use of preoperative adjunctive
radiation therapy must be considered. In an effort to increase the surgical
margins of dissection, resection of the inferior pubic rami and the lower
portion of the pubic symphysis has been used. Urinary diversion is
required.[6-10]
Ipsilateral inguinal node dissection is indicated if palpable ipsilateral
inguinal adenopathy is found on physical examination and confirmed to be
neoplasm by frozen section.[11]
Standard treatment options:
- Preoperative radiation followed by cystoprostatectomy, urinary diversion, and
penectomy with bilateral pelvic node dissection with or without inguinal node
dissection.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with posterior urethral cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Grigsby PW, Corn BW: Localized urethral tumors in women: indications for conservative versus exenterative therapies. J Urol 147 (6): 1516-20, 1992.
[PUBMED Abstract]
-
Sullivan J, Grabstald H: Management of carcinoma of the urethra. In: Skinner DG, deKernion JB: Genitourinary Cancer. Philadelphia: WB Saunders Company, 1978, pp 419-429.
-
Bracken RB, Johnson DE, Miller LS, et al.: Primary carcinoma of the female urethra. J Urol 116 (2): 188-92, 1976.
[PUBMED Abstract]
-
Sailer SL, Shipley WU, Wang CC: Carcinoma of the female urethra: a review of results with radiation therapy. J Urol 140 (1): 1-5, 1988.
[PUBMED Abstract]
-
Skinner EC, Skinner DG: Management of carcinoma of the female urethra. In: Skinner DG, Lieskovsky G, eds.: Diagnosis and Management of Genitourinary Cancer. Philadelphia, Pa: WB Saunders, 1988, pp 490-496.
-
Ray B, Canto AR, Whitmore WF Jr: Experience with primary carcinoma of the male urethra. J Urol 117 (5): 591-4, 1977.
[PUBMED Abstract]
-
Bracken RB, Henry R, Ordonez N: Primary carcinoma of the male urethra. South Med J 73 (8): 1003-5, 1980.
[PUBMED Abstract]
-
Klein FA, Whitmore WF Jr, Herr HW, et al.: Inferior pubic rami resection with en bloc radical excision for invasive proximal urethral carcinoma. Cancer 51 (7): 1238-42, 1983.
[PUBMED Abstract]
-
Webster GD: The urethra. In: Paulson DF, ed.: Genitourinary Surgery. Vol. 2. New York: Churchill Livingston, 1984, pp 399-583.
-
Donat S, Cozzi P, Herr H: Surgery of penile and urethral carcinoma. In: Walsh PC, Retik AB, Vaughan ED, et al., eds.: Campbell's Urology. 8th ed. Philadelphia: Saunders, 2002, pp 2983-2991.
-
Chao KS, Perez CA: Penis and male urethra. In: Perez CA, Brady LW, eds.: Principles and Practice of Radiation Oncology. 3rd ed. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 1717-1732.
Back to Top Urethral Cancer Associated With Invasive Bladder Cancer
Approximately 10% of patients having cystectomy for bladder cancer can be
expected to have or to later develop clinical neoplasm of the urethra distal to
the urogenital diaphragm. An autopsy series of patients having had cystectomy
for bladder cancer documented histologic evidence of urethral neoplasm in 20% of the patients.
A review from the Royal Marsden Hospital showed that those patients having
cystectomy for multiple and superficial bladder lesions have an especially high
incidence (34%) of urethral neoplasia.
The benefits of urethrectomy at the time of cystectomy need to be weighed
against the morbidity factors, which include added operating time, hemorrhage, and the
potential for perineal hernia. However, tumors found incidentally on
pathologic examination are much more likely to be superficial or in situ in
contrast to those that present with clinical symptoms at a later date when
the likelihood of invasion within the corporal bodies is high. The former
lesions are often curable, and the latter are only rarely so. Indications for
urethrectomy in continuity with cystoprostatectomy are:
- Visible tumor in the urethra.
- Positive swab cytology of the urethra.
- Positive margins of the membranous urethra on frozen section taken at the
time of cystoprostatectomy.
- Multiple in situ bladder tumors that extend onto the bladder
neck and proximal prostatic urethra.
If the urethra is not removed at the time of cystectomy, optimal follow-up
includes periodic cytologic evaluation of saline urethral washings.[1-4]
Standard treatment options:
- In continuity cystourethrectomy.
- Monitor urethral cytology and delayed urethrectomy.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with urethral cancer associated with invasive bladder cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Schellhammer PF, Whitmore WF Jr: Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 115 (1): 56-60, 1976.
[PUBMED Abstract]
-
Wolinska WH, Melamed MR, Schellhammer PF, et al.: Urethral cytology following cystectomy for bladder carcinoma. Am J Surg Pathol 1 (3): 225-34, 1977.
[PUBMED Abstract]
-
Gowing NFC: Urethral carcinoma associated with cancer of the bladder. Br J Urol 32(4): 428-438, 1960.
-
Hendry WF, Gowing NF, Wallace DM: Surgical treatment of urethral tumours associated with bladder cancer. Proc R Soc Med 67 (4): 304-7, 1974.
[PUBMED Abstract]
Back to Top Recurrent Urethral Cancer
Standard treatment options for female/male recurrent urethral cancer:
-
Locally recurrent urethral cancer after radiation therapy should be treated
by surgical excision.
- Locally recurrent urethral cancer after surgery alone should be considered
for combination radiation and wider surgical resection.[1]
Treatment options under clinical evaluation:
- Metastatic urethral cancer should be considered for clinical trials using
chemotherapy. Early evidence suggests that transitional cell cancer of the
urethra may respond favorably to the same chemotherapy regimens employed for
advanced transitional cell cancer of the bladder.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent urethral cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Scher HI, Yagoda A, Herr HW, et al.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J Urol 139 (3): 475-7, 1988.
[PUBMED Abstract]
Back to Top Get More Information From NCI
Call 1-800-4-CANCER
For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your questions.
Chat online
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 9:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
Write to us
For more information from the NCI, please write to this address:
- NCI Public Inquiries Office
- Suite 3036A
- 6116 Executive Boulevard, MSC8322
- Bethesda, MD 20892-8322
Search the NCI Web site
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use our “Best Bets” search box in the upper right hand corner of each Web page. The results that are most closely related to your search term will be listed as Best Bets at the top of the list of search results.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
Find Publications
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237), TTY at 1-800-332-8615.
Back to Top Changes to This Summary (01/09/2008)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Added Purpose of This PDQ Summary as a section.
Back to Top More Information
About PDQ
Additional PDQ Summaries
Important:
This information is intended mainly for use by doctors and other health care professionals. If you have questions about this topic, you can ask your doctor, or call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
Back to Top |